Primary Aldosteronism: Superselective Embolization vs. Laparoscopic Endocrine Curative Therapy

Launched by XINJIANG MEDICAL UNIVERSITY · Jul 15, 2024

Keywords

ClinConnect Summary

This clinical trial is studying two different treatments for a condition called primary aldosteronism, which affects the adrenal glands and can lead to high blood pressure. The trial is comparing adrenalectomy, a surgical procedure to remove the affected adrenal gland, with a less invasive method called super selective adrenal artery embolization, which involves blocking the blood supply to the adrenal gland. The goal is to find out which treatment is more effective and safer for patients.

To be eligible for this study, participants must be between 18 and 60 years old and have been diagnosed with primary aldosteronism based on specific medical guidelines. They should have unilateral disease, meaning that only one adrenal gland is affected. Participants will need to give their consent to be part of the study. Those with certain health conditions, such as severe liver disease or recent heart issues, or who are pregnant or breastfeeding, cannot participate. If you choose to participate, you can expect to be monitored closely throughout the trial to assess the outcomes of each treatment option.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-60
• • Diagnosed with primary aldosteronism according to the 2016 Clinical guidelines of the International Endocrine Society
• • Primary aldosteronism diagnosed according to international guidelines Unilateral disease by AVS or PET-CT criteria
• • Patients and their family members signed informed consent and agreed to participate in the study
• Exclusion Criteria:
• • A history of severe hypersensitivity to contrast media
• • Severe liver disease complications, such as thrombocytopenia, esophageal varices rupture bleeding, etc
• • Renal insufficiency (serum creatinine \> 176mmol/L or estimated glomerular filtration rate \< min.1.73m2)
• • Combined with other secondary hypertension, such as pheochromocytoma, hypercortisolism, renal vascular hypertension (such as renal artery stenosis), renin secretory tumor, renal parenchymatous hypertension, drug-induced hypertension (such as long-term use of glucocorticoids, contraceptives, estrogen, herbal medicines containing glycyrrhizin), pregnancy hypertension and other secondary hypertension
• • Combined with genetic diseases: such as false aldosteronism (Liddle syndrome), Bartter syndrome, familial hypokalemia and hypomagnesia (Gitelman syndrome)
• • Stroke, myocardial infarction and stent implantation occurred in the past 3 months
• • Serious other diseases, such as heart dysfunction (grade IV), acute infections, autoimmune diseases, various malignant tumors, etc
• • Participated in other clinical trials within the past 3 months
• • Pregnant, breastfeeding, or planning a pregnancy
• • Identify patients with alcohol allergy